Optipharm.CO.LTD - Asset Resilience Ratio

Latest as of June 2026: 13.32%

Optipharm.CO.LTD (153710) has an Asset Resilience Ratio of 13.32% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 153710 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩5.32 Billion

≈ $3.61 Million USD Cash + Short-term Investments

Total Assets

₩39.96 Billion

≈ $27.08 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Optipharm.CO.LTD's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Optipharm.CO.LTD assets under control.

Liquid Assets Composition Over Time

This chart breaks down Optipharm.CO.LTD's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Optipharm.CO.LTD long-term investment allocation to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩5.32 Billion	13.32%
Total Liquid Assets	₩5.32 Billion	13.32%

Asset Resilience Insights

Moderate Liquidity: Optipharm.CO.LTD has 13.32% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Optipharm.CO.LTD Industry Peers by Asset Resilience Ratio

Compare Optipharm.CO.LTD's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
LONZA GROUP UNSP.ADR 1/10 F:LO3A	Diagnostics & Research	3.04%
Healius Ltd AU:HLS	Diagnostics & Research	0.06%
Eurofins-Cerep SA PA:ALECR	Diagnostics & Research	13.42%
Gencurix Inc KQ:229000	Diagnostics & Research	4.01%
Sonic Healthcare Ltd AU:SHL	Diagnostics & Research	0.13%
Integral Diagnostics Ltd AU:IDX	Diagnostics & Research	0.03%
Australian Clinical Labs Ltd AU:ACL	Diagnostics & Research	4.11%
Monash Ivf Group Ltd AU:MVF	Diagnostics & Research	1.60%

Annual Asset Resilience Ratio for Optipharm.CO.LTD (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Optipharm.CO.LTD.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	18.64%	₩7.60 Billion ≈ $5.15 Million	₩40.77 Billion ≈ $27.63 Million	-29.86pp
2024-12-31	48.50%	₩21.01 Billion ≈ $14.24 Million	₩43.32 Billion ≈ $29.36 Million	-21.26pp
2023-12-31	69.76%	₩27.40 Billion ≈ $18.57 Million	₩39.28 Billion ≈ $26.62 Million	+5.25pp
2022-12-31	64.51%	₩26.57 Billion ≈ $18.00 Million	₩41.18 Billion ≈ $27.91 Million	-19.11pp
2021-12-31	83.63%	₩34.43 Billion ≈ $23.33 Million	₩41.17 Billion ≈ $27.90 Million	+14.99pp
2020-12-31	68.64%	₩28.36 Billion ≈ $19.22 Million	₩41.32 Billion ≈ $28.00 Million	-4.39pp
2019-12-31	73.03%	₩30.47 Billion ≈ $20.65 Million	₩41.72 Billion ≈ $28.27 Million	+12.24pp
2018-12-31	60.79%	₩25.92 Billion ≈ $17.57 Million	₩42.64 Billion ≈ $28.90 Million	+44.14pp
2017-12-31	16.65%	₩3.30 Billion ≈ $2.24 Million	₩19.84 Billion ≈ $13.45 Million	-2.89pp
2016-12-31	19.54%	₩4.02 Billion ≈ $2.72 Million	₩20.58 Billion ≈ $13.94 Million	--

pp = percentage points

About Optipharm.CO.LTD

KQ:153710 Korea Diagnostics & Research

Market Cap

$46.92 Million

₩69.24 Billion KRW

Market Cap Rank

#22227 Global

#1404 in Korea

Share Price

₩4720.00

Change (1 day)

+0.00%

52-Week Range

₩4260.00 - ₩6200.00

All Time High

₩28900.00